Paul A. Marks
Cell Biology Program
Memorial Sloan-Kettering Cancer Center
New York
NY 10021
USA
Name/email consistency: high
- The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Marks, P.A. Cell. Cycle (2004)
- Histone deacetylase inhibitors as new cancer drugs. Marks, P.A., Richon, V.M., Breslow, R., Rifkind, R.A. Curr. Opin. Oncol (2001)
- Histone deacetylases and cancer: causes and therapies. Marks, P., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T., Kelly, W.K. Nat. Rev. Cancer (2001)
- Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. Marks, P.A., Richon, V.M., Rifkind, R.A. J. Natl. Cancer Inst. (2000)